Data + Perspectives: Investigators Discuss the Optimal Management of Relapsed/Refractory Multiple Myeloma

Join us on Wednesday, September 9^th from 11:56 AM to 12:56 PM central time (12:56 PM to 1:56 PM eastern time).

Educational Lunch Meeting

In-person attendees, please check in 15 minutes before the start of the meeting.

MODULE 1: Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) 

• Similarities and differences in the cellular targets and mechanisms of action of the various bispecific antibodies for MM 
• Available efficacy and safety findings leading to the FDA approvals of the B-cell maturation antigen-directed bispecific antibodies teclistamab, elranatamab and linvoseltamab for heavily pretreated MM; optimal incorporation into current management algorithms 
• Published Phase III findings with teclistamab, either in combination (MajesTEC-3) or as monotherapy (MajesTEC-9), in earlier lines of treatment; potential clinical implications 
• Key efficacy and safety data with the GPRC5D-targeted bispecific antibody talquetamab for heavily pretreated disease; optimal selection of candidates for this agent 
• Recently reported positive findings with teclistamab in combination with talquetamab from the Phase III MonumenTAL-6 trial 
• Biological rationale for and published findings with the FcRH5-directed bispecific antibody cevostamab for R/R MM 
• Ongoing and planned Phase III research efforts with bispecific antibodies alone and in combination for MM 

MODULE 2: Utility of Antibody-Drug Conjugates for R/R MM 

• Mechanism of action and structural components of belantamab mafodotin 
• Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM 
• Extended efficacy and safety data from the Phase III DREAMM-7 and DREAMM-8 trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone, respectively, for patients who have received ≥1 prior line of therapy; overall survival findings from DREAMM-7 
• FDA approval and current role of belantamab mafodotin/bortezomib/dexamethasone in the management of R/R MM 
• Incidence, severity, mitigation and management of belantamab mafodotin-related adverse events, including ocular toxicities 
• Ongoing studies attempting to further elucidate the role of belantamab mafodotin for MM 

MODULE 3: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) and Other Promising Novel Agents and Strategies for R/R MM 

• Mechanism of action of CELMoDs; similarities and differences among iberdomide, mezigdomide and standard immunomodulatory drugs 
• Available data documenting the efficacy and safety of iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for patients with R/R MM 
• Emerging findings from the Phase III EXCALIBER-RRMM study indicating an improvement in minimal residual disease negativity rates with iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM 
• Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role 
• Rationale for the evaluation of CAR T-cell platforms with novel targets or manufacturing processes for R/R MM 
• Early data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel for R/R MM; FDA Regenerative Medicine Advanced Therapy Designation and ongoing evaluation in the QUINTESSENTIAL and QUINTESSENTIAL-2 studies 
• Preliminary efficacy and safety results from the Phase Ib/II DURGA-1 study of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy using the FasTCAR rapid manufacturing platform, for R/R MM; future development plans

Target Audience
This activity has been designed to meet the educational needs of hematologists, hematology-oncology fellows, medical oncologists and other healthcare professionals involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider published research findings and other clinical factors affecting the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM). 
• Assess available research data with B-cell maturation antigen (BCMA)-directed and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into current clinical algorithms. 
• Recall recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM. 
• Analyze the mechanism of action of, published and emerging efficacy and safety findings with and ongoing research efforts evaluating cereblon E3 ligase modulators to prepare for the potential clinical availability of these agents for patients with R/R MM. 
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed in the care of patients with R/R MM. 
• Recall available data with novel agents and strategies currently under investigation for R/R MM, and discuss clinical trial participation with eligible patients. 

CE Credit
CME credit information will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY
Dr Richardson — Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Karyopharm Therapeutics, Oncopeptides. Additional faculty to be announced.

MODERATOR
Dr Orlowski — Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, DEM BioPharma, GSK, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neurogene Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Contracted Research: Asylia Therapeutics Inc, Biotheryx, Heidelberg Pharma, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Sanofi.

EDITOR
Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and GSK.

George R Brown Convention Center
1001 Avenida de las Americas
Houston, TX 77010
Phone: (713) 853-8000

Meeting Room
Level 3 in Grand Ballroom B (Theater Room 2)

Map

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.